A new ranking by Boston Consulting Group (BCG) finds that, among global large-cap companies, U.S.-based biotech and pharmaceutical firms, on average, yield the greatest total shareholder return, reports Fortune.
Based on the metrics BCG followed, New York-based Regeneron Pharmaceuticals showed the largest return, and boasts an average 75.3% total shareholder return since 2011. Two other U.S. pharma firms that made the list in the top 10 global value creators included California-based Gilead Sciences and Cambridge, Massachusetts-based Biogen. The entire ranking by BCG can be found here.